Last reviewed · How we verify
Clear Care®
Clear Care® is a hydrogen peroxide-based contact lens cleaning and disinfection system that uses catalytic breakdown to remove protein and lipid deposits while disinfecting lenses.
Clear Care® is a hydrogen peroxide-based contact lens cleaning and disinfection system that uses catalytic breakdown to remove protein and lipid deposits while disinfecting lenses. Used for Cleaning, disinfection, and storage of soft contact lenses.
At a glance
| Generic name | Clear Care® |
|---|---|
| Also known as | hydrogen peroxide disinfecting solution |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Drug class | Contact lens care solution / disinfectant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The solution contains hydrogen peroxide (3%) which acts as a broad-spectrum antimicrobial agent, killing bacteria, fungi, and other microorganisms on contact lens surfaces. A platinum catalyst in the lens case converts residual hydrogen peroxide to water and oxygen, neutralizing the solution over 6 hours to make it safe for direct lens insertion. This dual-action mechanism provides both cleaning efficacy and safety.
Approved indications
- Cleaning, disinfection, and storage of soft contact lenses
Common side effects
- Eye irritation or discomfort
- Corneal abrasion (if used improperly without neutralization)
- Allergic reaction to solution components
Key clinical trials
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (PHASE1, PHASE2)
- Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Contact Lenses (NA)
- Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients (NA)
- A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis (PHASE2)
- Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses (NA)
- Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC) (PHASE1)
- The Effect of Lower Extremity Rotational Profile on Postural Control, Muscle Strength, Functional Capacity and Lower Extremity Function in Children With Generalized Joint Hypermobility
- Comparison of Clinical Performance of Two Monthly Replacement Toric Soft Contact Lenses (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |